Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenue Adjusted EBITDA (1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0% Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow (1) was $8.6 milli...
Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.